Cas 315-30-0 Msds Allopurinol Powder API Xanthine Oxidase Inhibitor

Basic Information
Place of Origin: China
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Drum/Bag
Delivery Time: Negotiation
Payment Terms: L/C, D/A, D/P, T/T
Supply Ability: Negotiation
Name: Allopurinol Synonyms: METHYLTHEOBROMIDE;6-dione,3,7-dihydro-1,3,7-trimethyl-1H-Purine-2;Alert-Pep;anhydrouscaffeine;Cafamil;Cafecon;Cafeina;caffedrine
Cas No: 315-30-0 Ec No: 206-250-9
Molecular Formula: C5H4N4O Molecular Weight: 136.111
Melting Point: 350 ºC Boiling Point: 290.8°C
Density: 1.4295
High Light:

cas no 315-30-0

,

chemical name 315-30-0

,

allopurinol api manufacturer

Allopurinol;CAS 315-30-0;API

Specification:

 

Name Allopurinol
Synonyms METHYLTHEOBROMIDE;6-dione,3,7-dihydro-1,3,7-trimethyl-1H-Purine-2;Alert-Pep;anhydrouscaffeine;Cafamil;Cafecon;Cafeina;caffedrine
Molecular Formula C5H4N4O
Molecular Weight 136.111
CAS Registry Number 315-30-0
EINECS Number 206-250-9
Melting point 350 ºC
Boiling point 290.8°C
Density 1.4295

 

Product Description:

 

Allopurinol (Zyloprim) is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM.Target: XAOAllopurinol (Zyloprim, and generics) is a drug used primarily to treat hyperuricemia (excess uric acid in blood plasma) and its complications, including chronic gout. It is a xanthine oxidase inhibitor which is administered orally. A common misconception is that allopurinol is metabolized by its target, xanthine oxidase, but this action is principally carried out by Aldehyde oxidase. The active metabolite of allopurinol is oxypurinol, which is also an inhibitor of xanthine oxidase. Allopurinol is almost completely metabolized to oxypurinol within two hours of oral administration, whereas oxypurinol is slowly excreted by the kidneys over 18–30 hours. For this reason, oxypurinol is believed responsible for the majority of allopurinol's effect.Allopurinol is a purine analog; it is a structural isomer of hypoxanthine (a naturally occurring purine in the body) and is an inhibitor of the enzyme xanthine oxidase. In addition to blocking uric acid production, inhibition of xanthine oxidase causes an increase in hypoxanthine and xanthine. While xanthine cannot be converted to purine ribotides, hypoxanthine can be salvaged to the purine ribotides adenosine and guanosine monophosphates. Increased levels of these ribotides may cause feedback inhibition of amidophosphoribosyl transferase, the first and rate-limiting enzyme of purine biosynthesis. Allopurinol, therefore, decreases uric acid formation and may also inhibit purine synthesis.

Product Use:

 

Allopurinol (Zyloprim) is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM.Target: XAOAllopurinol (Zyloprim, and generics) is a drug used primarily to treat hyperuricemia (excess uric acid in blood plasma) and its complications, including chronic gout. It is a xanthine oxidase inhibitor which is administered orally. A common misconception is that allopurinol is metabolized by its target, xanthine oxidase, but this action is principally carried out by Aldehyde oxidase. The active metabolite of allopurinol is oxypurinol, which is also an inhibitor of xanthine oxidase. Allopurinol is almost completely metabolized to oxypurinol within two hours of oral administration, whereas oxypurinol is slowly excreted by the kidneys over 18–30 hours. For this reason, oxypurinol is believed responsible for the majority of allopurinol's effect.Allopurinol is a purine analog; it is a structural isomer of hypoxanthine (a naturally occurring purine in the body) and is an inhibitor of the enzyme xanthine oxidase. In addition to blocking uric acid production, inhibition of xanthine oxidase causes an increase in hypoxanthine and xanthine. While xanthine cannot be converted to purine ribotides, hypoxanthine can be salvaged to the purine ribotides adenosine and guanosine monophosphates. Increased levels of these ribotides may cause feedback inhibition of amidophosphoribosyl transferase, the first and rate-limiting enzyme of purine biosynthesis. Allopurinol, therefore, decreases uric acid formation and may also inhibit purine synthesis.

 

Cas 315-30-0 Msds Allopurinol Powder API Xanthine Oxidase Inhibitor 0

 

Product Catalogue:

 

 

 

Number Cas Name
1 62-46-4 Alpha Lipoic Acid
2 303-98-0 Coenzyme Q10
3 6020-87-7 Creatine Monohydrate
4 110-17-8 Fumaric Acid
5 3416-24-8 Glucosamine
6 87-89-8 Inositol
7 73-22-3 L-Tryptophan
8 56-87-1 L-Lysine
9 24634-61-5 Potassium Sorbate
10 56038-13-2 Sucralose
11 107-35-7 Taurine
12 128-13-2 Ursodeoxycholic Acid/ UDCA
13 59-43-8 Vitamin B1
14 83-88-5 Vitamin B2
15 8059-24-310 Vitamin B6
16 68-19-9 Vitamin B12
17 50-81-7 Vitamin C
18 1406-18-4 Vitamin E
19 11138-66-2 Xanthan Gum

 

About us

 

 

Zhejiang chemical import and export co., LTD. (zhejiang), formerly known as zhejiang branch of China national chemical import and export corporation, was established in December 1980. In 1988, he was transferred from Sinochem Corporation to be in charge of Zhejiang Provincial Department of Commerce and was renamed Zhejiang Chemical Import and Export Company. In 2003, the company changed its name to Zhejiang Chemical Import and Export Co., Ltd after the reform of state-owned enterprise shareholding system.

In 2008, it was incorporated into Zhejiang International Trade Group (one of the top 500 enterprises in China) and became the core member of the group's business circulation sector. The registered capital of the company is 72.5 million yuan, of which 38% are owned by the state and 62% are owned by employees.
There are 195 employees in the company, more than 79% of whom have bachelor's degree, 36% of whom are graduate students, and more than 90% of the salesmen have pharmaceutical and chemical background. The company is mainly engaged in the import and export trade of pharmaceutical raw materials and intermediates, dyes, pesticides, basic chemicals, fine chemicals, food and feed additives, pharmaceutical preparations and other products. The company has established close economic and trade relations with more than 100 countries and regions around the world. The company has wholly-owned subsidiaries Ruike International Trade Co., Ltd., Zhejiang Ruikai Chemical Co., Ltd., Zhejiang Fukai Import and Export Co., Ltd., joint-stock enterprise Zhejiang Aotokang Pharmaceutical Group Co., Ltd.
In recent years, especially since the establishment of the new team in 2019, the company has adhered to the development led by the party building, energized by reform, and improved efficiency by management. The company has shown a steady upward momentum of development. In 2020, the company achieved revenue of 3.337 billion yuan, total profit of 56.12 million yuan, total import and export of 450 million dollars.

In 2019, the company was rated as China Council for the Promotion of International Trade (CCPIT) Recommended Certification Enterprise, Top 100 International Pharmaceutical Enterprises -- a high-quality supplier and partner in the international market; In 2020, Zhejiang Provincial Department of Commerce and other units rated as the province's epidemic prevention and medical materials import outstanding contribution enterprise, Zhejiang Provincial Tax Bureau identified as the export tax rebate enterprises.

Contact Details
William Wang

Phone Number : +86-13588430486

WhatsApp : +8613588430486